United Kingdom Pharmaceuticals & Healthcare Q3 2019
The outlook for the UK market is polarised by factors relating to Brexit outcomes. Our core remains a Brexit in nameonly in which significant disruption to medicine supply chains and regulatory processes is largely avoided. In this scenario, theregulatory landscape looks largely unchanged and, therefore, the market outlook is in line with current trends at low single-digitgrowth. A hard Brexit outcome where the UK leaves the EU without a deal in place has the potential to have a wide-ranging negativeimpact on the pharmaceuticals and healthcare sector. Though the likelihood of this outcome appears to be diminishing, thematerialisation of a hard Brexit could hurt research and development, reduce the pace of local innovative drug launches, impactmedicine exports to the EU and the reduce the availability of skilled labour for the National Health Service.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook